Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use
Launched by NOVA SCOTIA HEALTH AUTHORITY · Jul 17, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the impact of genetic counseling on preventing mental health issues related to cannabis use, particularly in young people. Researchers believe that certain genetic factors can make some individuals more vulnerable to the harmful effects of cannabis, which may increase the risk of severe mental illnesses like schizophrenia and bipolar disorder. By providing genetic counseling, the study aims to help participants understand their personal risks based on their family history and genetic makeup. The hope is that with this knowledge, young people will be less likely to use cannabis.
To be eligible for the trial, participants need to be between the ages of 12 and 21 and must be enrolled in the Families Overcoming Risks and Building Opportunities for Well-being (FORBOW) study. They should also be able to understand English well enough to engage with the counseling. Importantly, individuals with a current diagnosis of severe mental illness or certain developmental disabilities are not eligible to participate. Those who join the study can expect to receive personalized information about their genetic risks and guidance on how to make informed choices regarding cannabis use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Enrolment in the Families Overcoming Risks and Building Opportunities for Well-being (FORBOW) study.
- • Age between 12 and 21 years.
- • Knowledge of English sufficient to benefit from the intervention.
- • Capacity to provide informed consent at most recent FORBOW assessment.
- • Provision of consent to be contacted about future studies at most recent FORBOW assessment.
- Exclusion Criteria:
- • A diagnosis of severe mental illness (psychotic disorder, bipolar disorder, severe/recurrent depression) at baseline
- • Autism or intellectual disability of a degree that interferes with assessment (IQ \< 70)
About Nova Scotia Health Authority
The Nova Scotia Health Authority (NSHA) is a leading healthcare organization dedicated to enhancing the health and well-being of individuals and communities across Nova Scotia, Canada. As the largest provider of health services in the province, NSHA is committed to advancing clinical research and innovation through rigorous clinical trials that aim to improve patient care and outcomes. With a focus on collaboration, NSHA engages healthcare professionals, researchers, and patients to address pressing health challenges and contribute to the global body of medical knowledge. By fostering a culture of evidence-based practice and continual improvement, NSHA plays a pivotal role in shaping the future of healthcare delivery in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Halifax, Nova Scotia, Canada
Patients applied
Trial Officials
Rudolf Uher, MD, PhD
Principal Investigator
Nova Scotia Health Authority, Dalhousie University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials